tiprankstipranks

Immix Biopharma: EC grants orphan drug designation to NXC-201

Immix Biopharma announced that the European Commission has granted orphan drug designation to NXC-201 for the treatment of multiple myeloma.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue